New cocktail aims to Deep-Freeze myeloma
NCT ID NCT04268498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding daratumumab to a three-drug regimen (carfilzomib, lenalidomide, dexamethasone) works better than the three drugs alone for people newly diagnosed with multiple myeloma. About 310 participants will be randomly assigned to one of the treatments. The main goal is to see if the combination leads to less detectable cancer after eight cycles of therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab, carfilzomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this could offer a more effective initial treatment for multiple myeloma, potentially leading to longer remission and better disease control.
What could go wrong
This is a Phase 2 trial, so results are still early. The combination may cause more side effects, and it's not yet proven to be better than current standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institue
Salt Lake City, Utah, 84113, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612-9497, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Stony Brook University
Stony Brook, New York, 11794, United States
-
University of Miami
Miami, Florida, 33136, United States